de Lavallaz JDF, et al. - In this prospective diagnostic multicenter study that included a cohort of patients (aged > 45years) who sought admission to the emergency department (ED) for syncope, researchers assessed the diagnostic and prognostic accuracy of B-type Natriuretic Peptide (BNP), N-terminal proBNP (NT-proBNP), high-sensitivity cardiac troponin (hs-cTn), and hs-cTnI concentrations, alone and against the ones of clinical assessments. The diagnostic endpoint was cardiac syncope, diagnosed by two physicians who took into account all information available, including cardiac work-up and 1-year follow-up data. The diagnostic comparator was the EGSYS. The prognostic endpoints included death and major adverse cardiovascular events (MACE) at 30 days and 720 days. In ED patients with syncope, useful diagnostic and prognostic information was derived from BNP, NT-proBNP, hs-cTnT, and hs-cTnI levels. For all four biomarkers, the area under the curve (AUC) was 0.77-0.78 for diagnostic accuracy, which was superior to the one of EGSYS (AUC 0.68). For MACE, BNP, NT-proBNP, hs-cTnI, and hs-cTnT displayed moderate-to-good prognostic accuracy (AUC 0.75-0.79)— superior to ROSE, OESIL and San Fransisco Syncope Rule (SFSR) and inferior to the Canadian Syncope Risk Score (CSRS).